NEUBASE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4396 USD | -0.54% |
|
+2.23% | -40.60% |
| Mar. 26 | Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading | MT |
| Mar. 26 | US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings | MT |
Valuation
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 85.18 | 175.5 | 118.1 | 12.74 | 1.649 |
| Enterprise Value (EV) 1 | 85.18 | 175.5 | 118.1 | 12.74 | 1.649 |
| P/E ratio | -1.53 x | -8.53 x | -3.88 x | -0.38 x | -0.06 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | -25,807,057 x | - | - | - | - |
| FCF Yield | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 854 | 1,156 | 1,636 | 1,613 | 3,752 |
| Reference price 2 | 99.80 | 151.8 | 72.20 | 7.900 | 0.4396 |
| Announcement Date | 1/9/20 | 12/23/20 | 12/23/21 | 12/21/22 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Settembre | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -26.34 | -17.07 | -26.57 | -33.32 | -14.01 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -26.96 | -17.38 | -25.41 | -33.78 | -12.32 |
| Net income 1 | -26.96 | -17.38 | -25.41 | -33.78 | -12.32 |
| Net margin | - | - | - | - | - |
| EPS 2 | -65.20 | -17.80 | -18.60 | -20.80 | -7.290 |
| Free Cash Flow | -3.301 | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 1/9/20 | 12/23/20 | 12/23/21 | 12/21/22 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: September | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -5.9 | -8.839 | -7.169 | -7.305 | -9.929 | -8.361 | -7.723 | - | -4.164 | -3.688 | -2.813 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -5.522 | -8.663 | -7.158 | -7.729 | -9.924 | -8.492 | -7.632 | -4.369 | -4.093 | -3.447 | -1.821 |
| Net income 1 | -5.5 | -8.663 | -7.158 | -7.729 | -9.924 | -8.492 | -7.632 | -4.369 | -4.093 | -3.447 | -1.821 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -4.800 | -5.800 | -4.200 | -4.800 | -6.000 | -5.200 | -4.800 | -2.600 | -2.400 | -2.040 | -0.6600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/13/21 | 8/13/21 | 12/23/21 | 2/11/22 | 5/12/22 | 8/11/22 | 12/21/22 | 2/14/23 | 5/11/23 | 8/14/23 | 11/9/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | -3.3 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | 0.46 | - | - | - | 1.2 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 1/9/20 | 12/23/20 | 12/23/21 | 12/21/22 | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -40.60% | 1.65M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- NBSE Stock
- Financials NeuBase Therapeutics, Inc.
